Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis
- 10 October 2016
- journal article
- review article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 36 (1) , 25-34
Abstract
Our aim was to establish the comparative effectiveness of rheumatoid arthritis (RA) biologics, using a systematic review and network meta-analysis. The systematic review used randomized controlled trials (RCTs) in adults with RA who failed treatment with conventional disease-modifying agents for rheumatoid disease (cDMARDs). We compared the effectiveness of abatacept, adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, and rituximab to tocilizumab, a recent biologic with a different mechanism of action (anti-IL-6 receptor). A network meta-analysis (NMA) included the indirect and direct evidence previously selected. In total, 207 articles were included describing 68 RCTs. The NMA showed that tocilizumab monotherapy was superior to standard care (ACR20, OR 13.27, 95 % CrI [3.958, 43.98]; ACR50, 17.45 [10.18, 31.24]; ACR70, 37.77 [7.226, 216.3]; EULAR, 10.42 [1.963, 54.8]); and methotrexate (MTX; ACR50, OR 5.44 [4.142, 7.238]; ACR70, 7.364 [1.4, 30.83]; EULAR, 4.226 [1.184, 15.58]) at 26 weeks. Similarly, the combination of tocilizumab + MTX was significantly better than standard care/placebo and MTX alone for ACR20, ACR50, ACR70, and EULAR at 26 weeks (OR 18.63 [5.32, 66.81]; 24.27 [14.5, 41.91]; 46.13 [10.08, 277]; 14.23 [2.493, 84.02]; 4.169 [2.267, 7.871]; 5.44 [4.142, 7.238]; 8.731 [4.203, 19.29]; 7.306 [4.393, 13.04], respectively). At 52 weeks, compared to MTX alone, tocilizumab + MTX was significantly better for ACR20 and ACR50 response. Few significant differences were found between tocilizumab (alone or in combination) and any other biologics. Results must be considered in context with the limitations of the available evidence. This NMA suggests that tocilizumab was superior to cDMARDs and as effective as other biologics for RA.Keywords
Funding Information
- GlaxoSmithKline
This publication has 17 references indexed in Scilit:
- Annual Incremental Health Benefit Costs and Absenteeism Among Employees With and Without Rheumatoid ArthritisJournal of Occupational and Environmental Medicine, 2013
- Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel surveyArthritis Care & Research, 2012
- Changes in Utilization and Costs for Patients with Rheumatoid Arthritis, 1997 to 2006PharmacoEconomics, 2012
- The Economic Consequences of Rheumatoid ArthritisJournal of Occupational and Environmental Medicine, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2Value in Health, 2011
- Quantifying the economic burden of productivity loss in rheumatoid arthritisRheumatology, 2011
- Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA StudyArthritis Research & Therapy, 2010
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IArthritis & Rheumatism, 2007
- Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analysesBMJ, 2003